Roth Capital Partners resumed coverage of Actinium Pharmaceuticals (NYSE American:ATNM) with a “buy” rating and price target of $6. The stock closed at 73 cents on Oct.23.Read More
Roth Capital Partners initiated coverage of Actinium Pharmaceuticals (NYSE MKT:ATNM) with a “buy” rating and $5 price target. The stock closed at $1.66 on Wednesday.
“We believe it is an opportune time to explore the investment case of Actinium based on the late-stage nature of the lead asset, addressing unmet medical needs, clinical data in hand, and a broad set of upcoming catalysts,” writes analyst Joseph Pantginis.Read More
H.C. Wainwright has launched coverage of Actinium Pharmaceuticals (NASDAQ:ATNM) with a “buy” rating and a price target of $8. The stock closed at $1.98 on Friday.
"We believe that due to a long history of pivotal failures on top of a scarcity of treatment options, AML is likely to start enjoying some regulatory slack over the next few years, with Actinium well-positioned for value with two pedigreed assets tackling two different stages of the disease,” writes analyst Andrew Fein.Read More